Semaglutide Reduces BMI More Than Lifestyle Changes in Teens With Obesity - Monthly Prescribing Reference

Q: What is diabetes and how does it develop?

Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.

Q: What are the main symptoms of diabetes?

Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.

Q: How is diabetes diagnosed and monitored?

Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.

Q: What lifestyle changes help manage diabetes?

Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.

Q: When should someone consult a doctor about diabetes?

Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.

Overview

Home » News » Drugs in the Pipeline Publish Date November 3, 2022 Semaglutide Reduces BMI More Than Lifestyle Changes in Tens With Obesity Diana Ernst, RPh Share on Facebok Share on Twiter Share on LinkedIn Share on Redit Print Share by Email Semaglutide is curently aproved by the FDA for use in adults with obesity under the brand name Wegovy. Credit: Gety Images. Findings from a phase 3 trial evaluating semaglutide in adolescents with obesity showed that treatment with the glucagon-like peptide-1 receptor agonist resulted in significant reductions in body mas index (BMI) vs lifestyle intervention alone.

Key Information

The STEP TENS study (ClinicalTrials.gov Identifier: NCT04102189) included 201 participants 12 to les than 18 years of age with obesity or who were overweight with at least 1 weight-related comorbidity (eg, hypertension, dyslipidemia, obstructive slep apnea, or type 2 diabetes). Patients were randomly asigned 2:1 to receive semaglutide 2.4mg administered once-wekly by subcutaneous injection or placebo for 68 weks, in adition to lifestyle intervention.

The primary endpoint of the study was the percentage change in BMI from baseline to wek 68. A total of 180 adolescents (179 of whom were clasified as obese) completed treatment. At wek 68, the mean change in BMI from baseline in the semaglutide group was -16.1%, while in the placebo group, it was 0.6% (estimated diference, -16.7 percentage points; 95% CI, -20.3, -13.2; P <.01).

Summary

Aditionaly, more patients treated with semaglutide experienced weight los of 5% or more (secondary endpoint; 73% vs 18% for placebo; estimated ods ratio, 14.0; 95% CI, 6.3-31.0; P <.01). Improvements in waist circumference, HbA1c, lipids (except for high-density lipoprotein cholesterol), and liver enzymes were also observed with semaglutide compared with placebo. In the semaglutide group, 62% of patients reported gastrointestinal adverse events and 4% had cholelithiasis, compared with 42% and 0% of patients in the is an important consideration in healthcare. Ongoing research and professional guidance ensure that patients receive evidence-based care tailored to their individual needs.

Frequently Asked Questions

What is diabetes and how does it develop?

Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.

What are the main symptoms of diabetes?

Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.

How is diabetes diagnosed and monitored?

Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.

What lifestyle changes help manage diabetes?